BioSpecifics Technologies Corp (BSTC) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
BioSpecifics Technologies Corp (NASDAQ:BSTC) posted its earnings results on Friday. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.01, Bloomberg Earnings reports. BioSpecifics Technologies Corp had a net margin of 43.06% and a return on equity of 20.65%. The business had revenue of $6.52 million for the quarter, compared to analyst estimates of $6.59 million.
BioSpecifics Technologies Corp (BSTC) traded down $0.15 on Friday, hitting $43.63. 7,275 shares of the stock traded hands, compared to its average volume of 22,722. BioSpecifics Technologies Corp has a fifty-two week low of $41.95 and a fifty-two week high of $58.79. The company has a market cap of $311.50, a price-to-earnings ratio of 26.69 and a beta of 1.64.
BSTC has been the topic of several analyst reports. Zacks Investment Research raised shares of BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. BidaskClub lowered shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, HC Wainwright set a $72.00 target price on shares of BioSpecifics Technologies Corp and gave the stock a “buy” rating in a report on Thursday, August 10th.
TRADEMARK VIOLATION WARNING: “BioSpecifics Technologies Corp (BSTC) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/biospecifics-technologies-corp-bstc-posts-quarterly-earnings-results-beats-expectations-by-0-01-eps/1695542.html.
About BioSpecifics Technologies Corp
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.